In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed at $750.11 in the last session, down -3.86% from day before closing price of $780.19. In other words, the price has decreased by -$3.86 from its previous closing price. On the day, 0.99 million shares were traded. REGN stock price reached its highest trading level at $779.84 during the session, while it also had its lowest trading level at $748.2101.
Ratios:
We take a closer look at REGN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.67. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 24, 2025, HSBC Securities started tracking the stock assigning a Buy rating and target price of $255. On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $650.Scotiabank initiated its Sector Perform rating on November 13, 2025, with a $650 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Bassler Bonnie L sold 760 shares for $750.00 per share. The transaction valued at 570,000 led to the insider holds 1,548 shares of the business.
Bassler Bonnie L bought 760 shares of REGN for $570,000 on Nov 20 ’25. On Nov 07 ’25, another insider, Pitofsky Jason, who serves as the VP Controller of the company, sold 431 shares for $651.43 each. As a result, the insider received 280,766 and left with 4,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 79502237696 and an Enterprise Value of 71222779904. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.96, and their Forward P/E ratio for the next fiscal year is 17.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.53 while its Price-to-Book (P/B) ratio in mrq is 2.55. Its current Enterprise Value per Revenue stands at 4.999 whereas that against EBITDA is 16.381.
Stock Price History:
The Beta on a monthly basis for REGN is 0.37, which has changed by 0.00072038174 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $800.99, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is 18.30%, while the 200-Day Moving Average is calculated to be 25.41%.
Shares Statistics:
According to the various share statistics, REGN traded on average about 1.10M shares per day over the past 3-months and 1273910 shares per day over the past 10 days. A total of 103.50M shares are outstanding, with a floating share count of 101.18M. Insiders hold about 3.73% of the company’s shares, while institutions hold 85.42% stake in the company. Shares short for REGN as of 1763078400 were 2844265 with a Short Ratio of 2.60, compared to 1760486400 on 2927169. Therefore, it implies a Short% of Shares Outstanding of 2844265 and a Short% of Float of 2.86.
Earnings Estimates
The stock of Regeneron Pharmaceuticals, Inc (REGN) is currently being evaluated by 20.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $10.41, with high estimates of $11.39 and low estimates of $8.95.
Analysts are recommending an EPS of between $45.85 and $39.78 for the fiscal current year, implying an average EPS of $43.22. EPS for the following year is $37.38, with 9.0 analysts recommending between $44.9 and $29.56.
Revenue Estimates
According to 20 analysts,. The current quarter’s revenue is expected to be $3.75B. It ranges from a high estimate of $4.11B to a low estimate of $3.39B. As of. The current estimate, Regeneron Pharmaceuticals, Inc’s year-ago sales were $3.79BFor the next quarter, 20 analysts are estimating revenue of $3.42B. There is a high estimate of $3.78B for the next quarter, whereas the lowest estimate is $3.17B.
A total of 26 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.57B, while the lowest revenue estimate was $13.85B, resulting in an average revenue estimate of $14.19B. In the same quarter a year ago, actual revenue was $14.2BBased on 25 analysts’ estimates, the company’s revenue will be $14.95B in the next fiscal year. The high estimate is $16.51B and the low estimate is $13.33B.
